Hide Board Information

Show Board Information

Amylyx Pharmaceuticals Inc. AMLX

Board Mod: Add me as mod

Asst Mods:

Last Post: 06/03/2022 4:31:55 PM

Board Marks: 0

Posts Today: 0

Board Views Today: 3

Amylyx Pharmaceuticals Inc. (NASDAQ: AMLX) Stock Message Board

1. AMLX Company Profile

    

2. AMLX Time & Sales

    

3. AMLX Recent News

    

4. AMLX Filings

    

5. AMLX Financials

    

6. AMLX Buy Rating

Create New Post View All Posts Board Mark Banned

Post

Subject

Author

Posted On

2	AMLX 26% v21,1M c12.35 f58,5M H13.94 pMH14.05	znewcar1	06/03/2022 4:31:55 PM
1	CAN AMX0035 BE A POTENTIAL GAME CHANGER IN ALS?	AviseAnalytics	03/22/2022 9:39:23 AM

Recent Articles

• The Future of Deionized Water: A Market on the Rise
• Exploring the Best Preferred Stock ETFs for Stable Income
• Quantum Dot Display Market Set for Significant Growth by 2032
• Microcontroller Market Expected to Soar to USD 69.33 Billion
• Growth Forecast for Sustainable Active Ingredients Market
• ETFE Market Projected to Surpass $862 Million Amid Growth
• Growth Drivers in the Organosilicon Polymers Market Revealed
• NN, Inc. Celebrates Record New Business Wins and Growth Strategy
• Projected Surge in Plant-Based Meat Market to $25 Billion
• Provectus Biopharmaceuticals Boosts Innovative Eye Drug Initiative
• Duke Robotics Expands Horizons with New European Subsidiary
• Lincoln Electric to Host Webcast for Earnings Report Update
• Hikma and Emergent BioSolutions Forge Key Partnership for KLOXXADO
• Calumet Reveals Key Financial Insights for Q4 2024
• Akastor ASA Strengthens Control Over AKOFS Offshore Services
• Atlas Salt Enhances Project Management Using Oracle Cloud Solutions
• Kearney Boosts SAP Transformation Skills with Project Partners
• Akastor ASA Solidifies Control in AKOFS Offshore with New Shareholders Agreement
• Agora Data Appoints Industry Leader Jeremy Beck as Sales VP
• New England Donor Services Achieves Milestone in Organ Donation
• Verastem Oncology Advances Treatment Options with VS-7375
• Onto Innovation Secures Major DRAM Agreement for Growth
• Exploring the Exosome Research Market's Rapid Growth and Trends
• Innovative Advancements in 3D Process Control by Onto Innovation
• Bradley Company’s Elvari Accessories Celebrates Major Design Win
• Empowering Teens: The Journey of Goal-Setting for Success
• Firefly Neuroscience Unveils Innovative Brain Age Technology
• Captona Welcomes Brydne Slattery as New General Counsel
• Innovative Cargo Solution by GlobalX and United Airlines
• Emergent BioSolutions Expands Access to KLOXXADO® Nasal Spray
• Join Aramark's Conference Call to Discuss Q1 Fiscal 2025
• Italian Businesses Face Increased Pessimism Amid Trade Concerns
• NKT A/S Sees Significant Shareholding Shift by Norges Bank
• Signet Jewelers Faces Stock Drop Amid Guidance Adjustment
• Sinclair Incorporates New Financing Strategy for Growth
• Littelfuse Adjusts Investor Day Schedule Amid Leadership Shift
• Laser Photonics Drives Ambitious Growth Strategy Through 2025
• Macquarie's $5 Billion Boost for Applied Digital's Growth
• Tritent International Corp. Expands with FanTribe Acquisition
• CalciMedica Welcomes New Director to Boost Clinical Endeavors
• TG Therapeutics Aims for $540 Million in Revenue by 2025
• Prime Drink Group Welcomes New CFO to Lead Financial Strategies
• Investigation into H&E Equipment Services Fair Price for Shareholders
• Smartkem's Strategic Vision for 2025 and Recent Progress
• Bombardier's Upcoming Financial Results Announcement Overview
• Quanterix Shows Promising Growth as It Expands Offerings
• Soft2Bet's Growth Report Shows Exceptional 2024 Progress
• Pan Global Enhances Exploration for Copper-Gold-Tin in Spain
• Cyngn Inc. Gains $33 Million to Drive Autonomous Vehicle Expansion
• Ocular Therapeutix: AXPAXLI Trials Offer Hope for Eye Care